Clinical Trials
169 trialsSelective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NiloPost-STIM
University Hospital, Bordeaux
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
DANTE
Novartis
OPTIC
Takeda
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
ENESTfreedom
Novartis
ENESTop
Novartis
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
BosuPeg
St. Olavs Hospital
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Thomas Jefferson University
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
EDI-PIO
University of Campinas, Brazil
DESTINY
University of Liverpool
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Fred Hutchinson Cancer Center
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma
University Hospital, Antwerp
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Astellas Pharma Inc
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Stanford University
PTBCy
St. Petersburg State Pavlov Medical University
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.
UK-Haplo
University College, London
Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Fred Hutchinson Cancer Center
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
VeRitAs
Gruppo Italiano Malattie EMatologiche dell'Adulto
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
University of Nebraska
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hikma Pharmaceuticals LLC
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
National Institutes of Health Clinical Center (CC)
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Stanford University
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Medical College of Wisconsin
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
BEST
Gruppo Italiano Malattie EMatologiche dell'Adulto
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Memorial Sloan Kettering Cancer Center
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
University of Alabama at Birmingham
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer